

R&D PORTFOLIO December 2023 – 13 treatments delivered

	DISCOVERY			TRANSLATION			DEVELOPMENT		IMPLEMENTATION
	Screen	Hit-to-lead	Lead optimization	Pre-clinical	Phase I	Phase IIa/ Proof-of-concept	Phase IIb/III	Registration	Treatment access
Sleeping sickness							Acoziborole +		Fexinidazole for <i>T.b. gambiense</i> * + Fexinidazole for <i>Tb. rhodesiense</i> * + Nifurtimox-eflornithine combination therapy (NECT)*
Leishmaniasis	Screening		S07 series +	DNDI-6174 +	DNDI-6148 + DNDI-0690 + DNDI-6899 [GSK899 DDD853651] + CpG-D35 [DNDI-2319] + GSK245 [DDD1305143] +	LXE408 Novartis for VL +	Miltefosine + thermo-therapy for CL LAmB +/- miltefosine for PKDL (Asia)	Miltefosine + paromomycin for VL (Africa) Miltefosine + paromomycin or LAmB for PKDL (Sudan)	SSG + PM (East Africa)* New VL treatments (South Asia)* New treatments for VL/HIV* New VL treatments (Latin America)*
Chagas disease	Screening	Hit-to-lead	UW series +	Biomarkers	DNDI-6148 +		New benznidazole regimens		Benznidazole paediatric dosage forms*
Filaria: River blindness				DNDI-6166 [CC6166] +		Emodepside + Oxfendazole +			
Mycetoma								Fosravuconazole	New treatments for mycetoma
Dengue				Pre-clinical profiling					
HIV						SR 5FC [cryptococcal meningitis]			Super-booster for children with HIV/TB* 4-in-1 (ABC/3TC/LPV/r)* and other DAAs 2-in-1 LPV/r pellets 5FC, LAmB access [cryptococcal meningitis]
Hepatitis C									Ravidasvir* and other DAAs +
COVID-19/ Pandemic preparedness	Nucleo- side Booster		TMEM16 series + Moonshot + AVIDD ASAP +				ANTICOV		
Malaria >>									Fixed-dose combination ASMQ* Fixed-dose combination ASAQ*

>> Implementation transferred to the Medicines for Malaria Venture in 2015

+ New chemical entity (NCE) or NCE-enabling project

* Treatments delivered by DNDi with partners

▶ Treatments not delivered by DNDi, but DNDi working on access